After Lilly Powers Up Zepbound Supply, Analyst Wonders if Build-Out Is ‘Over Our Skis’

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scalia asked CEO David Ricks if the company has taken the GLP-1 supply chain too far.